4//SEC Filing
Cline Christopher R. 4
Accession 0001415889-25-023786
CIK 0001438533other
Filed
Sep 4, 8:00 PM ET
Accepted
Sep 5, 4:05 PM ET
Size
7.3 KB
Accession
0001415889-25-023786
Insider Transaction Report
Form 4
Cline Christopher R.
CHIEF FINANCIAL OFFICER
Transactions
- Sale
Common Stock
2025-09-04$19.71/sh−119$2,345→ 92,083 total - Sale
Common Stock
2025-09-03$18.20/sh−454$8,263→ 92,202 total
Footnotes (2)
- [F1]Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
- [F2]This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
Documents
Issuer
Travere Therapeutics, Inc.
CIK 0001438533
Entity typeother
Related Parties
1- filerCIK 0001943192
Filing Metadata
- Form type
- 4
- Filed
- Sep 4, 8:00 PM ET
- Accepted
- Sep 5, 4:05 PM ET
- Size
- 7.3 KB